From chronic to curable: Twice-yearly shot shows near-total HIV eradication
Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.
Gulf Live2h
A twice-yearly shot could help end AIDS, but will it get to everyone who needs it?
Nearly all of Latin America was excluded from the deal with drugmaker Gilead, sparking concern the world is missing a ...
MyNewsLA6h
Judge Denies Former Gilead COO Bid to Move Sexual Harassment Suit to Ventura
A judge Monday denied a bid by a former Gilead Sciences Inc. COO to transfer to Ventura County a sexual harassment lawsuit ...
Morrow County Sentinel7h
Highland defense leads way to win over MG
A strong defensive performance by the Highland boys’ basketball team propelled them to a 70-46 win over host Mount Gilead ...
devdiscourse8h
Breakthrough HIV Prevention: Twice-Yearly Shot Sparks Debate Over Global Access
The twice-yearly HIV prevention shot developed by Gilead has shown impressive results in preventing infections among both men ...
Morrow County Sentinel8h
MG teams pick up wins
Mount Gilead got into the win column on Friday when they took on Bucyrus and claimed a 79-40 decision. The Indians jumped out to a 24-7 lead after the first quarter and held a 43-22 edge going into ...
Gilead Sciences ticks upward for the eight consecutive session
Gilead Sciences (NASDAQ:GILD) shares continued gains for the eighth straight session, as the stock was up 1.5% on Monday. The ...
bovnews9h
Why Did Gilead Sciences, Inc. (GILD) Stock See 17.04% Surge in the Last 90 Days?
On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.46 which represents a slight increase of $0.05 or 0.05% from the prior close of $92.41. The stock opened at $92 ...